Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis

Mitchell S. Anscher, Feng Ming Kong, Lawrence B. Marks, Gunilla C. Bentel, Randy L. Jirtle

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Purpose: To determine whether changes in the plasma Transforming Growth Factor β1 (TGFβ1) concentration during radiotherapy could identify patients at risk for developing symptomatic radiation pneumonitis. Methods and Materials: Thirty-six patients who received radiation therapy with curative intent for lung cancer (n = 31), Hodgkin's disease (n = 4), or thymoma (n = 1) were evaluated prospectively. All patients had serial plasma TGFβ1 measurements obtained before, during, and after treatment. Plasma TGFβ1 was quantified using an enzyme-linked immunosorbent assay. Pneumonitis was defined clinically. Plasma TGFβ1 levels were considered to have normalized if the following occurred: the last on-treatment TGFβ1 level was both <7.5 ng/ml and lower than the pretreatment level. Results: Thirteen of these 36 patients developed pneumonitis. Significant changes in plasma TGFβ1 levels during treatment were seen only in the subset of patients whose TGFβ1 levels were >7.5 ng/ml at baseline (n = 22). Failure of plasma TGFβ1 to normalize by the end of treatment, as defined above, much more accurately identified patients at risk for symptomatic pneumonitis if their baseline TGFβ1 was >7.5 ng/ml than if it was <7.5 ng/ml. Conclusions: Changes in plasma TGFβ1 levels during radiotherapy appears to be a useful means by which to identify patients at risk for the development of symptomatic radiation pneumonitis, particularly in the subset of patients whose pretreatment TGFβ1 levels are >7.5 ng/ml.

Original languageEnglish (US)
Pages (from-to)253-258
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume37
Issue number2
DOIs
StatePublished - Jan 15 1997

Fingerprint

Radiation Pneumonitis
beta factor
Transforming Growth Factors
Transforming Growth Factor beta
radiation therapy
Radiotherapy
radiation
Pneumonia
Thymoma
Hodgkin Disease
lungs
enzymes
Lung Neoplasms
Therapeutics
cancer
Enzyme-Linked Immunosorbent Assay

Keywords

  • Complications
  • Radiation therapy
  • Transforming Growth Factor β1

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. / Anscher, Mitchell S.; Kong, Feng Ming; Marks, Lawrence B.; Bentel, Gunilla C.; Jirtle, Randy L.

In: International Journal of Radiation Oncology Biology Physics, Vol. 37, No. 2, 15.01.1997, p. 253-258.

Research output: Contribution to journalArticle

Anscher, Mitchell S. ; Kong, Feng Ming ; Marks, Lawrence B. ; Bentel, Gunilla C. ; Jirtle, Randy L. / Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. In: International Journal of Radiation Oncology Biology Physics. 1997 ; Vol. 37, No. 2. pp. 253-258.
@article{a9322d868b474464a448f60f3f6e5301,
title = "Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis",
abstract = "Purpose: To determine whether changes in the plasma Transforming Growth Factor β1 (TGFβ1) concentration during radiotherapy could identify patients at risk for developing symptomatic radiation pneumonitis. Methods and Materials: Thirty-six patients who received radiation therapy with curative intent for lung cancer (n = 31), Hodgkin's disease (n = 4), or thymoma (n = 1) were evaluated prospectively. All patients had serial plasma TGFβ1 measurements obtained before, during, and after treatment. Plasma TGFβ1 was quantified using an enzyme-linked immunosorbent assay. Pneumonitis was defined clinically. Plasma TGFβ1 levels were considered to have normalized if the following occurred: the last on-treatment TGFβ1 level was both <7.5 ng/ml and lower than the pretreatment level. Results: Thirteen of these 36 patients developed pneumonitis. Significant changes in plasma TGFβ1 levels during treatment were seen only in the subset of patients whose TGFβ1 levels were >7.5 ng/ml at baseline (n = 22). Failure of plasma TGFβ1 to normalize by the end of treatment, as defined above, much more accurately identified patients at risk for symptomatic pneumonitis if their baseline TGFβ1 was >7.5 ng/ml than if it was <7.5 ng/ml. Conclusions: Changes in plasma TGFβ1 levels during radiotherapy appears to be a useful means by which to identify patients at risk for the development of symptomatic radiation pneumonitis, particularly in the subset of patients whose pretreatment TGFβ1 levels are >7.5 ng/ml.",
keywords = "Complications, Radiation therapy, Transforming Growth Factor β1",
author = "Anscher, {Mitchell S.} and Kong, {Feng Ming} and Marks, {Lawrence B.} and Bentel, {Gunilla C.} and Jirtle, {Randy L.}",
year = "1997",
month = "1",
day = "15",
doi = "10.1016/S0360-3016(96)00529-9",
language = "English (US)",
volume = "37",
pages = "253--258",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis

AU - Anscher, Mitchell S.

AU - Kong, Feng Ming

AU - Marks, Lawrence B.

AU - Bentel, Gunilla C.

AU - Jirtle, Randy L.

PY - 1997/1/15

Y1 - 1997/1/15

N2 - Purpose: To determine whether changes in the plasma Transforming Growth Factor β1 (TGFβ1) concentration during radiotherapy could identify patients at risk for developing symptomatic radiation pneumonitis. Methods and Materials: Thirty-six patients who received radiation therapy with curative intent for lung cancer (n = 31), Hodgkin's disease (n = 4), or thymoma (n = 1) were evaluated prospectively. All patients had serial plasma TGFβ1 measurements obtained before, during, and after treatment. Plasma TGFβ1 was quantified using an enzyme-linked immunosorbent assay. Pneumonitis was defined clinically. Plasma TGFβ1 levels were considered to have normalized if the following occurred: the last on-treatment TGFβ1 level was both <7.5 ng/ml and lower than the pretreatment level. Results: Thirteen of these 36 patients developed pneumonitis. Significant changes in plasma TGFβ1 levels during treatment were seen only in the subset of patients whose TGFβ1 levels were >7.5 ng/ml at baseline (n = 22). Failure of plasma TGFβ1 to normalize by the end of treatment, as defined above, much more accurately identified patients at risk for symptomatic pneumonitis if their baseline TGFβ1 was >7.5 ng/ml than if it was <7.5 ng/ml. Conclusions: Changes in plasma TGFβ1 levels during radiotherapy appears to be a useful means by which to identify patients at risk for the development of symptomatic radiation pneumonitis, particularly in the subset of patients whose pretreatment TGFβ1 levels are >7.5 ng/ml.

AB - Purpose: To determine whether changes in the plasma Transforming Growth Factor β1 (TGFβ1) concentration during radiotherapy could identify patients at risk for developing symptomatic radiation pneumonitis. Methods and Materials: Thirty-six patients who received radiation therapy with curative intent for lung cancer (n = 31), Hodgkin's disease (n = 4), or thymoma (n = 1) were evaluated prospectively. All patients had serial plasma TGFβ1 measurements obtained before, during, and after treatment. Plasma TGFβ1 was quantified using an enzyme-linked immunosorbent assay. Pneumonitis was defined clinically. Plasma TGFβ1 levels were considered to have normalized if the following occurred: the last on-treatment TGFβ1 level was both <7.5 ng/ml and lower than the pretreatment level. Results: Thirteen of these 36 patients developed pneumonitis. Significant changes in plasma TGFβ1 levels during treatment were seen only in the subset of patients whose TGFβ1 levels were >7.5 ng/ml at baseline (n = 22). Failure of plasma TGFβ1 to normalize by the end of treatment, as defined above, much more accurately identified patients at risk for symptomatic pneumonitis if their baseline TGFβ1 was >7.5 ng/ml than if it was <7.5 ng/ml. Conclusions: Changes in plasma TGFβ1 levels during radiotherapy appears to be a useful means by which to identify patients at risk for the development of symptomatic radiation pneumonitis, particularly in the subset of patients whose pretreatment TGFβ1 levels are >7.5 ng/ml.

KW - Complications

KW - Radiation therapy

KW - Transforming Growth Factor β1

UR - http://www.scopus.com/inward/record.url?scp=0030978490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030978490&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(96)00529-9

DO - 10.1016/S0360-3016(96)00529-9

M3 - Article

C2 - 9069294

AN - SCOPUS:0030978490

VL - 37

SP - 253

EP - 258

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -